Cargando…

Tumour Markers: Rationale Use

Detalles Bibliográficos
Autores principales:	Müller, Mathias M., Vogl, Marietta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Communications and Publications Division (CPD) of the IFCC 2005
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6008973/ https://www.ncbi.nlm.nih.gov/pubmed/29942234

Ejemplares similares

Rationales for the Use of Cancer Stem Cells Markers in the Staging of Papillary Thyroid Carcinoma
por: Mahmood, Noah Abd-Alkader, et al.
Publicado: (2019)

Impact of tumour rupture risk on the oncological rationale for the surgical treatment choice of gastrointestinal stromal tumours
por: Peparini, Nadia
Publicado: (2023)

Assessing tumour markers.
por: Tate, H.
Publicado: (1981)

Use of thyroglobulin as a tumour marker
por: Indrasena, Buddhike Sri Harsha
Publicado: (2017)

A note on the rationale for estimating genealogical coancestry from molecular markers
por: Toro, Miguel Ángel, et al.
Publicado: (2011)

Tumour markers in breast cancer.
por: Cove, D. H., et al.
Publicado: (1979)

Inhibition of angiogenesis and murine tumour growth by laminarin sulphate.
por: Hoffman, R., et al.
Publicado: (1996)

Rationale of using different biological therapies in rheumatoid arthritis
por: Geyer, Matthias, et al.
Publicado: (2010)

Cancers Screening in an Asymptomatic Population by Using Multiple Tumour Markers
por: Wang, Hsin-Yao, et al.
Publicado: (2016)

Objective measurement of therapeutic response in breast cancer using tumour markers.
por: Robertson, J. F., et al.
Publicado: (1991)

The value of tumour markers in lung cancer.
por: Gomm, S. A., et al.
Publicado: (1988)

Rationale, Study Design, and Cohort Characteristics for the Markers for Environmental Exposures (MEE) Study
por: Lucia, Rachel McFarland, et al.
Publicado: (2020)

Serum proteins as tumour markers for breast cancer.
por: Mattison, P., et al.
Publicado: (1981)

Maximum recovery after knee replacement – the MARKER study rationale and protocol
por: Lin, Chung-Wei Christine, et al.
Publicado: (2009)

Frequency of serum tumour marker monitoring in patients with non-seminomatous germ cell tumours.
por: Seckl, M. J., et al.
Publicado: (1990)

The predictive value of immunohistochemical markers in untreated Wilms’ tumour: are they useful?
por: Ghanem, Mazen A., et al.
Publicado: (2011)

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours.
por: Trotter, M. J., et al.
Publicado: (1989)

Tumour Markers: Impact and Prospects
por: Coombes, R. C.
Publicado: (1980)

Genetic markers in oligodendroglial tumours
por: Velnar, Tomaz, et al.
Publicado: (2010)

Tumour marker antigens during menses and pregnancy.
por: Touitou, Y., et al.
Publicado: (1989)

Frequency of serum tumour marker monitoring.
por: Colls, B. M.
Publicado: (1991)

Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours
por: Bulusu, V R, et al.
Publicado: (2013)

Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation
por: Marampon, Francesco, et al.
Publicado: (2019)

Comparison of four serum tumour markers in the diagnosis of colorectal carcinoma.
por: van der Schouw, Y. T., et al.
Publicado: (1992)

Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.
por: Baudin, E., et al.
Publicado: (1998)

Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.
por: Biesma, B., et al.
Publicado: (1992)

Tumour-marker levels and prognosis in malignant teratoma of the testis.
por: Germa-Lluch, J. R., et al.
Publicado: (1980)

An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours.
por: Raleigh, J. A., et al.
Publicado: (1994)

Tumour markers of prognosis in colorectal cancer
por: McLeod, H L, et al.
Publicado: (1999)

Immunohistochemical detection of a hypoxia marker in spontaneous canine tumours.
por: Cline, J. M., et al.
Publicado: (1990)

Using Sensors in Organizational Research—Clarifying Rationales and Validation Challenges for Mixed Methods
por: Müller, Jörg, et al.
Publicado: (2019)

The Rationale for Using Rifabutin in the Treatment of MDR and XDR Tuberculosis Outbreaks
por: Sirgel, Frederick A., et al.
Publicado: (2013)

Tumour markers, Virus, Neck dissection, Miscellaneous
Publicado: (1998)

Rationale for Using Immunopotentiators in Domestic Food Animals
por: BLECHA, FRANK, et al.
Publicado: (1990)

Serum Tumour Markers in Testicular Germ Cell Tumours: Frequencies of Elevated Levels and Extents of Marker Elevation Are Significantly Associated with Clinical Parameters and with Response to Treatment
por: Dieckmann, Klaus-Peter, et al.
Publicado: (2019)

Expression of Potential Dermal Progenitor Cell Markers in the Tumour and Stroma of Skin Adnexal Malignant and Benign Tumours
por: Quist, Sven R., et al.
Publicado: (2019)

Deciphering Host Genotype-Specific Impacts on the Metabolic Fingerprint of Listeria monocytogenes by FTIR Spectroscopy
por: Grunert, Tom, et al.
Publicado: (2014)

High-throughput mRNA and miRNA profiling of epithelial-mesenchymal transition in MDCK cells
por: Shukla, Priyank, et al.
Publicado: (2015)

Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
por: Wang, Xi-De, et al.
Publicado: (2007)

Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers
por: Chan, K C A, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_d9tok1j70vq6i7j4cadio7hv20